Asia-Pacific Consensus on Long-term and Sequential Therapy for Osteoporosis

Objectives: This study aimed to present the Asia-Pacific consensus on long-term and sequential therapy for osteoporosis, offering evidence-based recommendations for the effective management of this chronic condition. The primary focus is on achieving optimal fracture prevention through a comprehensive, individualized approach.

Methods: A panel of experts convened to develop consensus statements by synthesizing the current literature and leveraging clinical expertise. The review encompassed long-term anti-osteoporosis medication goals, first-line treatments for individuals at very high fracture risk, and the strategic integration of anabolic and antiresorptive agents in sequential therapy approaches.

Results: The panelists reached a consensus on 12 statements. Key recommendations included advocating for anabolic agents as the first-line treatment for individuals at very high fracture risk and transitioning to antiresorptive agents following the completion of anabolic therapy. Anabolic therapy remains an option for individuals experiencing new fractures or persistent high fracture risk despite antiresorptive treatment. In cases of inadequate response, the consensus recommended considering a switch to more potent medications. The consensus also addressed the management of medication-related complications, proposing alternatives instead of discontinuation of treatment.

Conclusions: This consensus provides a comprehensive, cost-effective strategy for fracture prevention with an emphasis on shared decision-making and the incorporation of country-specific case management systems, such as fracture liaison services. It serves as a valuable guide for healthcare professionals in the Asia-Pacific region, contributing to the ongoing evolution of osteoporosis management.

Citing Articles

Optimizing bone health in people living with HIV: insights from a network meta-analysis of randomized controlled trials.

Wang J, Chung S, Wu P, Tu Y, Lai P, Tai T EClinicalMedicine. 2025; 81:103103.

PMID: 40040862 PMC: 11876934. DOI: 10.1016/j.eclinm.2025.103103.

Efficacy and safety of sequential therapy for primary osteoporosis with bone formation promoters followed by bone resorption inhibitors: a meta-analysis.

Liu Y, Liu X, Wu Y, Luo T J Orthop Surg Res. 2025; 20(1):147.

PMID: 39920732 PMC: 11803957. DOI: 10.1186/s13018-025-05545-1.

Erythropoietin treatment and osteoporotic fracture risk in hemodialysis patients: A nationwide population-based study.

Lee C, Sung F, Hung P, Muo C, Wu M, Huang T Osteoporos Sarcopenia. 2025; 10(4):157-164.

PMID: 39835325 PMC: 11742347. DOI: 10.1016/j.afos.2024.11.002.

References

McClung M, Bolognese M, Brown J, Reginster J, Langdahl B, Shi Y . Skeletal responses to romosozumab after 12 months of denosumab. JBMR Plus. 2021; 5(7):e10512. PMC: 8260819. DOI: 10.1002/jbm4.10512. View

Ramchand S, David N, Lee H, Bruce M, Bouxsein M, Tsai J . The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension. J Bone Miner Res. 2022; 38(1):26-34. PMC: 10098948. DOI: 10.1002/jbmr.4737. View

Reid I . Osteoporosis treatment: focus on safety. Eur J Intern Med. 2013; 24(8):691-7. DOI: 10.1016/j.ejim.2013.03.012. View

Muller D, Pulm J, Gandjour A . Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review. Value Health. 2012; 15(2):284-98. DOI: 10.1016/j.jval.2011.11.030. View

Mignot M, Taisne N, Legroux I, Cortet B, Paccou J . Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int. 2017; 28(12):3431-3438. DOI: 10.1007/s00198-017-4215-9. View

Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A . Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open-Label Trial. JBMR Plus. 2018; 2(5):289-294. PMC: 6139701. DOI: 10.1002/jbm4.10054. View

Solling A, Harslof T, Langdahl B . Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study. J Bone Miner Res. 2021; 36(7):1245-1254. DOI: 10.1002/jbmr.4305. View

Taguchi A, Hagino H, Inoue D, Endo N, Society J . Cooperation between physicians and dentists for osteonecrosis of the jaw: a 2022 Japanese survey. J Bone Miner Metab. 2023; 41(6):829-837. DOI: 10.1007/s00774-023-01458-3. View

Lin T, Yang C, Yang Y, Lin S . Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther. 2011; 90(1):109-16. DOI: 10.1038/clpt.2011.62. View

10.

Ensrud K, Crandall C . Osteoporosis. Ann Intern Med. 2017; 167(3):ITC17-ITC32. DOI: 10.7326/AITC201708010. View

11.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A . Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007; 41(1):122-8. DOI: 10.1016/j.bone.2007.03.011. View

12.

Curtis J, Westfall A, Cheng H, Lyles K, Saag K, Delzell E . Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008; 23(9):1435-41. PMC: 2574615. DOI: 10.1359/jbmr.080418. View

13.

Hiligsmann M, Williams S, Fitzpatrick L, Silverman S, Weiss R, Reginster J . Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum. 2019; 49(2):184-196. DOI: 10.1016/j.semarthrit.2019.01.006. View

14.

Lewiecki E, Dinavahi R, Lazaretti-Castro M, Ebeling P, Adachi J, Miyauchi A . One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2018; 34(3):419-428. DOI: 10.1002/jbmr.3622. View

15.

Hadji P, Zanchetta J, Russo L, Recknor C, Saag K, McKiernan F . The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2011; 23(8):2141-50. DOI: 10.1007/s00198-011-1856-y. View

16.

Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. 2020; 26(Suppl 1):1-46. DOI: 10.4158/GL-2020-0524SUPPL. View

17.

Kothawala P, Badamgarav E, Ryu S, Miller R, Halbert R . Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007; 82(12):1493-501. DOI: 10.1016/S0025-6196(11)61093-8. View

18.

Bone H, Cosman F, Miller P, Williams G, Hattersley G, Hu M . ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018; 103(8):2949-2957. PMC: 6097601. DOI: 10.1210/jc.2018-00163. View

19.

Tai T, Tsai Y, Shih C, Li C, Chang Y, Huang C . Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter. J Formos Med Assoc. 2023; 122 Suppl 1:S65-S73. DOI: 10.1016/j.jfma.2023.04.004. View

20.

Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y . Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study. Bone. 2022; 162:116480. DOI: 10.1016/j.bone.2022.116480. View